ストックスクリーナーアプリを入手
140.98
1.29%
-1.84
アフターアワーズ：
141.14
0.16
+0.11%
Insmed Inc (INSM) 最新ニュース
Insmed Inc stock (US4576693075): Is the rare disease pipeline strong enough to unlock new upside? - AD HOC NEWS
Insmed Incorporated (INSM) Stock Analysis: Potential 47% Upside With Strong Buy Ratings - DirectorsTalk Interviews
Insmed Stock Hits Day Low of $135.73 Amid Price Pressure - Markets Mojo
INSM Reiterates by Roth Capital -- Price Target Maintained at $2 - GuruFocus
Insmed chair and CEO William Lewis sells $1.54m in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INSMED (INSM) CEO exercises options and sells 10,699 shares under 10b5-1 plan - Stock Titan
Roth Mkm Reaffirms "Buy" Rating for Insmed (NASDAQ:INSM) - MarketBeat
Roth MKM Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $212 - Moomoo
William Lewis lists INSM share sales (NASDAQ: INSM) in Form 144 filing - Stock Titan
Guggenheim raises Insmed stock price target to $230 on Arikayce By Investing.com - Investing.com Canada
Guggenheim Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $230 - Moomoo
Insmed, Inc. (NASDAQ:INSM) Short Interest Update - MarketBeat
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Insmed Inc stock (US4576693075): Is brensocatib approval the real test for rare disease growth? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Purchases Shares of 435,442 Insmed, Inc. $INSM - MarketBeat
INSM Maintained by RBC Capital -- Price Target Raised to $216 - GuruFocus
Insmed Sees Favorable Physician Feedback on Brinsupri, RBC Capital Markets Says - Moomoo
Oak Ridge Investments LLC Trims Position in Insmed, Inc. $INSM - MarketBeat
RBC Raises Price Target on Insmed to $216 From $212, Keeps Outperform Rating - marketscreener.com
RBC Capital Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $216 - Moomoo
RBC Capital raises Insmed stock price target on Brinsupri outlook By Investing.com - Investing.com Canada
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
EBIT per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Institution Moves: What are the future prospects of Insmed Incorporated2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller trims stake - MSN
US Stocks Recap: Is URTY a cyclical or defensive stockGap Up & Verified Swing Trading Watchlist - baoquankhu1.vn
Risk Analysis: Is Insmed Incorporated stock a buy or sell2026 Trade Ideas & Reliable Momentum Entry Alerts - baoquankhu1.vn
Insmed (INSM): Top QQQ Stock to Buy Now - Yahoo Finance
Insmed Achieves $280 Million Trading Volume, Secures Leading Market Position Despite Positive Analyst Ratings and Clinical Challenges - Bitget
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More - 24/7 Wall St.
What is HC Wainwright's Estimate for Insmed FY2027 Earnings? - MarketBeat
Is It Too Late To Consider Insmed (INSM) After A 146% One Year Surge? - Yahoo Finance
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
FRANKLIN GROWTH OPPORTUNITIES FUND's Insmed Inc(INSM) Holding History - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock - Investing.com Nigeria
Insmed (INSM) Halts Brensocatib R&D After Trial Setback - GuruFocus
Insmed chair and CEO William Lewis sells $1.75 million in stock By Investing.com - Investing.com South Africa
Insmed Insider Sold Shares Worth $1,746,336, According to a Recent SEC Filing - Moomoo
Insmed (INSM) CEO sells shares, exercises options under 10b5-1 plan - Stock Titan
Trial Failure in the Skin Does Not Dent Insmed Drug’s Potential in the Lungs - MedCity News
Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake - Yahoo Finance
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure - Yahoo Finance
Insmed Drug Misses Primary Goal, Program Axed - Benzinga
Insmed freezes Brinsupri’s HS programme on Phase II failure - Yahoo Finance
Mizuho Trims Price Target on Insmed to $202 From $206, Keeps Outperform Rating - marketscreener.com
Insmed drops skin disorder candidate after mid-stage trial setback - Seeking Alpha
Insmed drops HS program for Brinsupri after Phase IIb miss - The Pharma Letter
Insmed stock falls after failed hidradenitis suppurativa trial By Investing.com - Investing.com South Africa
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Fails to Meet Endpoints - Minichart
AVIP AB Mid Cap Core Portfolio's Insmed Inc(INSM) Holding History - GuruFocus
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
Insmed (INSM) Maintains Buy Rating Despite Trial Setback - GuruFocus
Insmed (INSM) to Resume Trading After Phase 2b Study Results - GuruFocus
1.83%
1.81%
大文字化:
|
ボリューム (24 時間):